Josh Farkas argues IV nalbuphine is underused despite strong theoretical and clinical support, especially when respiratory drive is fragile.
note to self: use more IV nalbuphine
it's supported by robust theoretical & clinical evidence
especially useful in patients with tenuous respiratory drive
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare